Ascelia Pharma AB (publ) (STO:ACE)

Market Cap	406.44M
Revenue (ttm)	n/a
Net Income (ttm)	-94.78M
Shares Out	126.82M
EPS (ttm)	-1.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	809,824
Average Volume	1,717,440
Open	3.155
Previous Close	3.150
Day's Range	3.125 - 3.240
52-Week Range	2.050 - 5.230
Beta	1.07
RSI	49.71
Earnings Date	Nov 5, 2025

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headq...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACE